[artículo] 
inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103

Título :	MDMA and MDMA- assisted therapy
Tipo de documento:	texto impreso
Autores:	Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor
Fecha de publicación:	2025
Artículo en la página:	pp. 79-103
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT).
Resumen:	MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024.
Link:	./index.php?lvl=notice_display&id=31560

[artículo] MDMA and MDMA- assisted therapy [texto impreso] / Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor . - 2025 . - pp. 79-103.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103

Palabras clave:	Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT).
Resumen:	MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024.
Link:	./index.php?lvl=notice_display&id=31560